European anatomic pathology information systems provider Dedalus Group and AI-powered cancer diagnostics firm Ibex Medical Analytics have announced the launch of a fully integrated end-to-end AI-powered digital pathology solution for cancer diagnosis.
The new solution is now commercially available in major European markets and sets a new standard for anatomic pathology laboratory digitisation by seamlessly integrating Ibex's Galen platform into Dedalus' comprehensive digital pathology (DP) solution. It enables full digitisation of anatomic pathology laboratories with a next-generation Anatomic Pathology Information System (AIS) and DP solution, harnessing the power of data and AI for assisted case prioritisation, advanced image analysis, and reproducible diagnoses.
The increasing demand for pathology services posed by the growing number of cancer patients and global shortage of trained pathologists, leads pathology laboratories to actively seek efficiency enhancing solutions that enable laboratories to maintain high accuracy levels while reducing time to diagnosis and optimising diagnostic workflows.
The joint solution leverages the capabilities of dedalus' end-to-end digital pathology solution, featuring a novel, holistic approach for digitising anatomic pathology laboratories, together with Ibex’s Galen, the most widely deployed AI technology in pathology, now seamlessly integrated to enable efficient routine work from a single application. Galen’s AI-powered findings are available on the joint solution, that supports pathologists in the diagnosis of prostate, breast and gastric biopsies with improved accuracy, AI-powered decision support tools, streamlined reporting, improved laboratory efficiency, and increased diagnostic confidence.
“As the premier anatomic pathology information systems provider in Europe, Dedalus takes great pride in partnering with Ibex to introduce this integrated solution. This collaboration harmonises Dedalus' expertise in pathology information systems with Ibex's cutting-edge AI-powered diagnostics. It reflects our commitment to advancing anatomic pathology, equipping pathologists with a state-of-the-art solution that fosters increasingly accurate and timely diagnoses. The potential for enhancing patient outcomes is substantial, and we are leading the way in this transformative journey," says Marlen Suller, Head of In Vitro Diagnostics Business Unit at Dedalus.
“Our solutions lead the AI revolution in pathology with algorithms and tools that drive consistent improvement in the quality and efficiency of cancer diagnosis in our growing customer base,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics. “We are excited to partner with Dedalus, the leading diagnostic software provider in Europe, to embed AI deeply within their information system and offer pathologists a truly end-to-end solution combining AI findings with digital images, patient information and laboratory processes together in a single unified workflow – a game changer for pathology departments in Europe.”
